The first randomised multidomain lifestyle prevention trial conducted across Latin America has reported a small but statistically significant cognitive advantage for a structured programme over flexible health advice, in a paper published online in The Lancet on 13 July 2026 and presented the same day at the Alzheimer's Association International Conference in London. LatAm-FINGERS (ClinicalTrials.gov NCT06492967) was a single-blind, multicentre, randomised controlled trial. Of 1,719 people screened, 1,065 aged 60 to 77 with a raised dementia risk score (CAIDE 6 or above) and suboptimal cognitive test performance were randomly assigned 1:1 to a systematic lifestyle intervention (539) or a flexible lifestyle intervention (526), across 11 countries and 12 centres in Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, the Dominican Republic, Ecuador, Mexico, Peru and Uruguay. A Puerto Rico centre was excluded from the analysis. Enrolment ran from 27 October 2021 to 7 July 2023, and the last participant completed follow-up on 7 November 2025.

The structured arm combined supervised physical activity, dietary counselling, computerised cognitive training and management of cardiovascular risk factors, each adapted to local foods, languages and settings; the comparison arm received regular health advice. The trial's stated primary outcomes were feasibility, assessed with selected RE-AIM measures, and the trajectory of a global cognitive composite over two years. Scores rose in both groups: a mean annual change of 0.31 standard deviations (95% confidence interval 0.28 to 0.34) in the structured arm and 0.20 (0.17 to 0.23) in the advice arm, a between-group difference of 0.11 standard deviations per year, reported as about 55 per cent greater annual improvement. Domain results favoured the structured arm for episodic memory (0.14 per year), executive function (0.04) and processing speed (0.04). Dropout was 15.2 per cent in the structured arm and 20.2 per cent in the advice arm (p=0.042).

The trial sits in the World-Wide FINGERS network, which began with the Finnish FINGER trial and includes the US POINTER study reported in 2025, and it was funded by the Alzheimer's Association. Latin America has one of the fastest growing senior populations and a high prevalence of the vascular and metabolic risk factors linked to cognitive decline, yet the region has been thinly represented in prevention research. The investigators frame the result as evidence that such programmes can be delivered with harmonised procedures in low-income and middle-income settings.

The counterpoint is in the design and the size of the gap. Both arms received an active programme, so the 0.11 figure is the distance between two interventions rather than between an intervention and nothing, and participants and intervention staff knew their assignment, though outcome assessors were masked. The trial measured cognitive test scores over two years, not diagnoses of dementia, and it cannot say which component of the package did the work. In an accompanying Lancet Comment, Juan Fortea of Hospital de la Santa Creu i Sant Pau in Barcelona and colleagues wrote that interventions built on diet, exercise, social engagement and vascular care "cannot simply be transferred from high-income settings to Latin America without cultural and contextual adaptation", and noted that dementia prevention is becoming a testable public health strategy rather than a settled one.